Boehringer to sell stake in Hikma
Boehringer’s stake in the firm equates to around 16.4%
Read Moreby Selina McKee | Jun 23, 2020 | News | 0
Boehringer’s stake in the firm equates to around 16.4%
Read Moreby Anna Smith | Jan 9, 2020 | News | 0
The product will be officially announced prior to launch.
Read Moreby Selina McKee | Nov 9, 2018 | News | 0
Hikma Pharmaceuticals and Vectura have signed a deal to develop and market generic versions of GlaxoSmithKline’s Ellipta portfolio, utilising the latter’s Open-Inhale-Close dry powder inhaler device.
Read Moreby Selina McKee | Mar 12, 2018 | News | 0
US regulators have upheld a prior decision rejecting Hikma and Vectura’s generic formulation of GlaxoSmithKline’s asthma and chronic obstructive pulmonary syndrome therapy Advair Diskus.
Read Moreby Selina McKee | May 11, 2017 | News | 0
Chippenham, UK-based Vectura and its partner Hikma Pharmaceuticals have announced a major setback in the US after VR315, a generic version of GlaxoSmithKline’s asthma/COPD inhaler Advair Diskus, was rejected by the FDA.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
